Joyce Feagin, MD
Hematology & Oncology · Shreveport, LANPI 1285660316
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,991 of the $18,642 with a category attached, or 69.7%. 39 manufacturers reported payments, led by AstraZeneca at 58.6% of the total.
Across 177 payments — averaging $105.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Eisai Inc.$1K
- Daiichi Sankyo Inc.$566
- AbbVie$383
- plus $2K from 33 others
Across 26 payments — averaging $2941.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$27K
- E.r. Squibb & Sons, L.L.C.$21K
- Morphosys AG$14K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- Pharmacyclics LLC, An Abbvie Company$2K
What the payments were for
- Consulting fees$12,99170%
- Speaking & faculty fees$3602%
- Travel & lodging$1811%
- Food & beverage$2,58514%
- Education$5293%
- Other$1,99511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $10,924 |
| Novartis | 41 | $2,367 |
| E.r. Squibb & Sons, L.L.C. | 10 | $1,419 |
| Eisai Inc. | 2 | $1,229 |
| Daiichi Sankyo Inc. | 12 | $566 |
| AbbVie | 16 | $383 |
| Johnson & Johnson | 12 | $335 |
| Sanofi | 8 | $146 |
| Merck | 6 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Pfizer | 5 | $89 |
| Myriad Genetic Laboratories, Inc. | 1 | $83 |
| Genentech USA, Inc. | 5 | $80 |
| Tempus AI, Inc | 3 | $73 |
| Regeneron Healthcare Solutions, Inc. | 3 | $61 |
| Tesaro, Inc. | 2 | $46 |
| Incyte Corporation | 3 | $46 |
| Bayer | 3 | $44 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $40 |
| GSK | 2 | $37 |
| Astellas Pharma US Inc | 2 | $32 |
| Acrotech Biopharma Inc. | 2 | $28 |
| Boehringer Ingelheim | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $19 |
| Pharmaessentia USA Corporation | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Genmab U.S., Inc. | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| Partner Therapeutics, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Beone Medicines USA, Inc. | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,642 in reported general payments places this provider in the 80th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 45 | $828,393 |
| ImbruvicaIbrutinib | 32 | $519,068 |
| CabometyxCabozantinib S-Malate | 12 | $316,228 |
| PomalystPomalidomide | 12 | $233,440 |
| CalquenceAcalabrutinib Maleate | 14 | $217,171 |
| LonsurfTrifluridine/Tipiracil Hcl | 16 | $148,252 |
| Imatinib Mesylate | 20 | $145,801 |
| EliquisApixaban | 27 | $21,365 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,548 |
| XareltoRivaroxaban | 12 | $6,604 |
| Letrozole | 134 | $2,847 |
| Anastrozole | 189 | $2,356 |
| Enoxaparin Sodium | 11 | $1,829 |
| Exemestane | 13 | $1,699 |
| Hydroxyurea | 48 | $956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $14 | $828,39345 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $40 | $519,06832 claims |
| Exelixis Inc.Cabometyx | $15 | $316,22812 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,419 | $233,44012 claims |
| AstraZenecaCalquence | $10,924 | $217,17114 claims |
| Taiho Oncology, Inc.Lonsurf | $19 | $148,25216 claims |
| PfizerEliquis | $89 | $21,36527 claims |
| GSKTrelegy Ellipta | $37 | $7,54811 claims |
| Johnson & JohnsonXarelto | $335 | $6,60412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Shreveport
- Prakash PeddiShreveport$405K
- Kevin GallagherShreveport$145K
- Maxwell McDonaldShreveport$123K
- Kirtan KotichaShreveport$45K
- Tharwat GhattasShreveport$25K
- Richard MansourShreveport$16K
- Kavitha BeedupalliShreveport$15K
- Steven BoniolShreveport$14K
- Gary BurtonShreveport$10K
- Hana SafahBaton Rouge$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.